What is the Latest Status Update for the Testosterone Therapy and AndroGel Litigation?
Following the publication of several independent studies and FDA warnings about the risk of cardiovascular problems from testosterone treatments, more than 6,000 Androgel lawsuits, Testim lawsuits, Axiron lawsuits and other claims have been filed against manufacturers of testosterone replacement therapy drugs, alleging that the medications were aggressively marketed to men who had little or no need for the treatments, while withholding information about important safety risks.
Given similar questions of fact and law presented in cases filed throughout the federal court system, the testosterone litigation was centralized before U.S. District Judge Matthew F. Kennelly in the Northern District of Illinois in June 2014, for coordinated discovery and pretrial management.
Known as the testosterone MDL (multidistrict litigation), the consolidated proceedings have involved several “bellwether” pools, with representative cases against different manufacturers prepared for early trial dates, which are designed to help gauge how juries may respond to certain evidence and testimony that may be repeated throughout the litigation.
Find Out If You or a Loved One May Be Eligible to Join the Testosterone Litigation
All of the lawsuits involve similar allegations, indicating that men suffered heart attacks, strokes, blood clots or other serious, and sometimes fatal injuries, as a result of side effects of testosterone drugs.
In July 2017, the first jury to hear evidence in a testosterone therapy lawsuit indicated that AbbVie, the maker of Androgel, should be required to pay $150 million in punitive damages, which were designed to punish the pharmaceutical company for fraudulent misrepresentations about the safety of their treatment.
While the verdict was overturned during post-trial motions, and a new trial was ordered, the award provided clear signals about the potential liability drug makers may face if they fail to reach testosterone settlements.
In October 2017, a second jury awarded a combined total of $140 million in compensatory and punitive damages to one plaintiff in another bellwether trial over Androgel testosterone therapy. However, dozens of additional cases are being prepared for bellwether trials through 2018 and 2019.
Join the Androgel Litigation
While the early bellwether verdicts are not binding on other plaintiffs, evidence strongly suggests that the drug manufacturers knew about the potential risk of heart problems from Androgel and other testosterone drugs, yet inadequate warnings were provided to men and the medical community.
As the testosterone litigation continues to move forward, the lawyers at Saiontz & Kirk, P.A. are continuing to review potential claims for men who have suffered injuries from testosterone therapy, such as:
- Heart Attack
- Blood Clots
- Wrongful Death
To learn more about the current status of the litigation or determine if you, a friend or family member may be entitled to financial compensation for a testosterone drug injury, call 1-800-522-0102 or request a free and confidential consultation.